Tau PET in neurodegenerative diseases manifesting dementia

Nobuyuki Okamura, Ryuichi Harada, Shozo Furumoto, Yukitsuka Kudo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Noninvasive imaging of tau pathology can contribute to the early and differential diagnosis of neurodegenerative diseases and evaluating the efficacy of disease-specific therapies. For in vivo imaging of tau protein deposits in the human brain, PET tracers should exhibit high binding affinity to the ß-pleated sheet structure of PHF-tau, high binding selectivity to tau over amyloid-ß, and high blood-brain barrier permeability. Several tau PET tracers have been developed and tested in humans. Recent tau PET studies have demonstrated a high amount of tracer retention in sites that have a predilection for the cortical deposition of tau protein aggregates in patients with Alzheimer's disease (AD). The amount of tracer retention is closely associated with dementia severity and neurodegeneration. Therefore, tau PET is expected to be useful for tracking disease progression, assessing disease severity, and accurately predicting dementia prognosis. In this chapter, we will discuss recent progress in the development of tau-selective PET tracers and clinical PET studies using these tracers.

Original languageEnglish
Title of host publicationNeuroimaging Diagnosis for Alzheimer's Disease and Other Dementias
PublisherSpringer Japan
Pages199-210
Number of pages12
ISBN (Electronic)9784431551331
ISBN (Print)9784431551324
DOIs
Publication statusPublished - 2017 Aug 29

Keywords

  • Alzheimer's disease
  • Imaging
  • Neurofibrillary tangles
  • Positron-emission tomography
  • Tau proteins

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Tau PET in neurodegenerative diseases manifesting dementia'. Together they form a unique fingerprint.

Cite this